Medikamenten-induzierte Oberbauchbeschwerden

Zusammenfassung

Gastrointestinale Beschwerden gehören zu den häufigsten Nebenwirkungen von Medikamenten. Das Spektrum an Symptomen ist breit. Häufig berichten die Patienten über Oberbauchschmerzen, vorzeitiges Sättigungsgefühl, Druckgefühl im Oberbauch, epigastrische oder retrosternale Schmerzen, Blähungen, Durchfälle oder Obstipation. Ein Teil dieser Beschwerden wird von den Patienten und/oder Ärzten auf den Oberbauch und speziell auf den Magen bezogen. „Magenschmerzen“, dh epigastrische Schmerzen, treten dabei selten isoliert auf sondern meist in Verbindung mit weiteren Symptomen wie Druckgefühl, Völlegefühl oder vorzeitiges Sättigungsgefühl, Übelkeit, Erbrechen – eine als Dyspepsie bezeichnete Symptomkonstellation. Bei der Häufigkeit dieser Beschwerden in der Bevölkerung und den zahlreichen Medikamenten, die manche Patienten einnehmen, kann es im Einzelfall sehr schwierig sein zu erkennen, ob es sich um Medikamenten-induzierte Beschwerden oder um spontan entstandene Symptome handelt.

Abstract

Gastrointestinal symptoms are among the most common side effects of drugs. There is a broad spectrum of symptoms. Patients often report upper abdominal pain, an early sense of satiety, epigastric discomfort or pain in the upper abdomen or behind the breastbone, flatulence, diarrhoea or constipation. Some of these symptoms are attributed to the stomach or upper abdomen by the patient and/or the physician. “Stomach pain”, pain in the epigastric region, occurs in most cases in combination with other symptoms such as a feeling of pressure in the upper abdomen or bloating, early satiety, nausea or vomiting – a combination called dyspepsia. Given the high frequency of these symptoms in the general population and the large number of medications many patients are taking, it can be very difficult in a given patient to differentiate between drug-induced side effects and spontaneously occurring symptoms.

Schlüsselwörter

Bauchschmerz - Medikamenten-Nebenwirkungen - medikamentös-induzierte Oberbauchbeschwerden - Protonenpumpenhemmer - NSAR

Keywords

abdominal pain - adverse effects - drug-induced dyspepsia - proton pump inhibitor - NSAID

• Literatur

• 1 Straus WL, Ofman JJ, MacLean C et al. Do NSAIDs cause dyspepsia? A meta-analysis evaluating alternative dyspepsia definitions. Am J Gastroenterol 2002; 97: 1951-1958
• 2 Aronson JK. Meyler’s side effects of drugs. The International Encyclopedia of Adverse Drug Reactions and Interactions. 15.. Aufl. Oxford: Elsevier Science; 2006
• 3 Hallas J, Bytzer P. Screening for drug related dyspepsia: an analysis of prescription symmetry. Eur J Gastroenterol Hepatol 1998; 10: 27-32
• 4 Bytzer P, Hallas J. Drug-induced symptoms of functional dyspepsia and nausea. A symmetry analysis of one million prescriptions. Aliment Pharmacol Ther 2000; 14: 1479-1484
• 5 Lagergren J, Bergström R, Adami HO, Nyrén O. Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med 2000; 133: 165-175
• 6 Zografos GN et al. Drug-induced esophagitis. Dis Esophagus 2009; 22: 633-637
• 7 de Groen PC, Lubbe DF, Hirsch LJ et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996; 335: 1016-1021
• 8 Tutuian R. Adverse effects of drugs on the esophagus. Best Pract Res Clin Gastroenterol 2010; 24: 91-97
• 9 Walker J, Robinson J, Stewart J, Jacob S. Does enteric-coated aspirin result in a lower incidence of gastrointestinal complications compared to normal aspirin?. Interact Cardiovasc Thorax Surg 2007; 6: 519-522
• 10 Sostres C, Gargallo CJ, Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther 2013; 15  (Suppl. 03) S3
• 11 Nitsche CJ, Jamieson N, Lerch MM, Mayerle JV. Drug induced pancreatitis. Best Prac Res Clin Gastroenterol 2010; 24: 143-155
• 12 Chappel C, Neumann D, Thompson VJ et al. Dyspeptic symptoms and sleep disturbance: A report from a large observational study in low-dose acetylsalicylic acid users. Gastroenterology 2009; 136  (Suppl. 01) A-488
• 13 Davies M, Wilton LV, Shakir SA. Safety profile of esomeprazole: results of a prescription-event monitoring study of 11 595 patients in England. Drug Saf 2008; 31: 313-323
• 14 Chan FK, To KF, Wu JC et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002; 359: 9-13
• 15 Labenz J, Blum AL, Bolten WW et al. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial. Gut 2002; 51: 329-335
• 16 Ekström P, Carling L, Wetterhus PE et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol 1996; 31: 753-758
• 17 Cullen D, Bardhan KD, Eisner M et al. Primary gastroduodenal prophylaxis with omeprazol for non-steroidal anti-infammatory drug users. Aliment Pharmacol Ther 1998; 12: 135-140
• 18 Hawkey C, Talley NJ, Yeomans ND et al. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol 2005; 100: 1028-1036
• 19 Fischbach W, Malfertheiner P, Hoffman JC et al. S3-Leitlinie „Helicobacter pylori und gastroduodenale Ulkuskrankheit” der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS). Z Gastroenterol 2009; 47: 68-102
• 20 Scheiman JM, Devereaux PJ, Herlitz J et al. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart 2011; 97: 797-802
• 21 Scheiman JM, Herlitz J, Veldhuyzen van Zanten SJ et al. Esomeprazole for prevention and resolution of upper gastrointestinal symptoms in patients treated with low-dose acetylsalicylic acid for cardiovascular protection: the OBERON trial. J Cardiovasc Pharmacol 2013; 61: 250-257
• 22 Laine L, Smith R, Min K et al. Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2006; 24: 751-767
• 23 Chan FK, Lanas A, Scheiman J et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010; 376: 173-179
• 24 Jarupongprapa S, Ussavasodhi P, Katchamart W. Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis. J Gastroenterol 2013; 48: 830-838
• 25 Laine L, Curtis SP, Cryer B et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007; 369: 465-473
• 26 Spiegel BM, Farid M, Dulai GS et al. Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis. Am J Med 2006; 119: 448.e27-36
• 27 Gernber T. 72-jähriger Tumorpatient mit gastrointestinaler Blutung. Dtsch med Wochenschr 2010; 135: 1123-1124